Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis

Tumour hypoxia has been shown to increase mutation rate, angiogenesis, and metastatic potential, and decrease response to conventional therapeutics. Improved tumour oxygenation should translate into increased treatment response. Exogenous recombinant erythropoietin (rEpo) has been recently shown to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardee, M E, Kirkpatrick, J P, Shan, S, Snyder, S A, Vujaskovic, Z, Rabbani, Z N, Dewhirst, M W, Blackwell, K L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361536/
https://www.ncbi.nlm.nih.gov/pubmed/16288305
http://dx.doi.org/10.1038/sj.bjc.6602846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361536/
https://www.ncbi.nlm.nih.gov/pubmed/16288305
http://dx.doi.org/10.1038/sj.bjc.6602846

Ejemplares similares